subslover
4日前
Phio Pharmaceuticals Announces Completion of Enrollment in Third Safety Cohort in PH-762 Phase 1b Dose-Escalation Study
Newsfile Corp.
Newsfile Corp
Marlborough, Massachusetts--(Newsfile Corp. - March 5, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio announced today that it has fulfilled the required enrollment for safety in its third dose cohort in its Phase 1b dose escalating clinical study for their lead compound PH-762. The company plans to initiate screening of the fourth dose cohort in early April.
Phio's Phase 1b study (NCT 06014086) is a multi-center, dose-escalating clinical trial designed to evaluate the safety and tolerability of neoadjuvant use of intratumoral PH-762 in cutaneous squamous cell carcinoma, melanoma, or Merkel cell carcinoma. This study assesses the tumor response and determines the recommended dose for further study of PH-762.
"We are excited with the rapid completion of enrollment of the third safety cohort," said Robert Bitterman, CEO of Phio Pharmaceuticals. "We look forward to rapidly advancing the study to bring an innovative, alternative treatment option to patients with skin carcinomas."
Zilidium
2月前
S-1 Does the forecast call for pain...
Pros: If PHIO demonstrates strong progress in its clinical trials, communicates a clear and effective use of proceeds, and generates positive clinical and financial milestones, the additional 5.9 million shares is a reasonable trade-off for long-term growth.
Cons: If there’s limited progress (no reason to believe there will be with the recent news) delays, or ambiguity about the company’s ability to monetize its pipeline, the market may view the dilution as detrimental, which will be bad, very, very bad indeed.
When will the warrants expire??
Series E Warrants: Exercisable until December 2029 @ $2.51
Series F Warrants: Exercisable until December 2029 @ 2.00
Series G, H, and I Warrants: Exercisable until January 2027 $3.00
Warrants must be exercised voluntarily, and holders typically do so when the market price exceeds the warrant exercise price.
This may get sloppy, so hold on.
Invest-in-America
2月前
PHIO: See ME, below, workin' on that $10.00, right now!!!
"PLEASE, Oh Lord, give me $10.00 even on PHIO today, & I'll donate 50% of my profits to THE STARVATION ARMY, and SAINT JUDE'S CHILDREN'S REFORMATORY!!"
Invest-in-America
2月前
PHIO: And the RED INK continues!! (But then, hopefully tomorrow they PR a proven Phase-3 CURE for every Cancer known to MANKIND!!!)
"Well, we're WAITING --- for your NEXT wonderful Cancer cure PR, oh great PHIO Company!!! And, will ya DUMP more shares to Market, the DAY thereafter???!!! We sincerely HOPE NOT!!!"